Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

advexin

Known as: INGN 201, INGN-201, RPR/INGN-201 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Multimodal approaches combining drugs that differentially function is the most popular regimen for treating human cancer… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Purpose: Most recurrent squamous cell carcinomas of the head and neck have a dysfunctional p53 tumor suppressor pathway… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Review
2009
Review
2009
Li-Fraumeni syndrome is an autosomal dominant disorder first reported by Drs Li and Fraumeni in 1969. Malkin was the first to… Expand
  • table 1
  • table 2
Is this relevant?
2008
2008
 
  • table 1
Is this relevant?
Review
2006
Review
2006
Mutations in the p53 gene are the most frequent genetic alterations in human tumours, occurring in ∼ 50% of all cancers. The p53… Expand
Is this relevant?
2006
2006
  • Hepeng Jia
  • Nature Reviews Drug Discovery
  • 2006
  • Corpus ID: 34361597
Experience in clinic is raising issues that Western researchers will not have seen before 
  • figure 1
  • figure 2
Is this relevant?
2006
2006
China in November became the first country to have approved two drugs based on gene therapy. The approvals have fueled quick… Expand
Is this relevant?
2004
2004
Purpose: INGN 201 (Ad-p53) is a replication-defective adenoviral vector that encodes a wild-type p53 gene driven by the… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2003
Highly Cited
2003
PURPOSE We designed a prospective single arm Phase II study to evaluate the feasibility and mechanisms of apoptosis induction… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Review
2003
Review
2003
  • BioDrugs : clinical immunotherapeutics…
  • 2003
  • Corpus ID: 41101388
Introgen's adenoviral p53 gene therapy [INGN 201, ADVEXIN] is in clinical development for the treatment of various cancers. The… Expand
Is this relevant?